Double-blind, parallel, randomized, placebo-controlled 12-week efficacy and safety assessment of ZR-02-01 [fentanyl] in the treatment of chronic, moderate to severe osteoarthritis (OA) pain

Trial Profile

Double-blind, parallel, randomized, placebo-controlled 12-week efficacy and safety assessment of ZR-02-01 [fentanyl] in the treatment of chronic, moderate to severe osteoarthritis (OA) pain

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors ZARS Pharma
  • Most Recent Events

    • 04 Jun 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual patient number is 202 according to ClinicalTrials.gov.
    • 04 Jun 2012 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top